Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2008

01.04.2008 | Epidemiology

Interest in breast cancer chemoprevention among older women

verfasst von: Jennifer Tjia, Ellyn Micco, Katrina Armstrong

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives:

The study aim is to describe interest in breast cancer chemoprevention among older women without a history of breast cancer and to determine whether aging-related factors such as diminished life expectancy, increasing comorbidity and medication burden attenuate chemoprevention interest.

Design:

Cross-sectional survey.

Setting:

University of Pennsylvania Health System.

Participants:

Four-hundred fifty-seven community-dwelling women aged 60–65 years old who were potentially eligible for breast cancer chemoprevention according to guidelines linking risk and eligibility to age.

Measurements:

Interest in breast cancer chemoprevention, Gail model breast cancer risk, perceived breast cancer risk, breast cancer worry, self-reported health status and comorbidities, and self-reported perceived life expectancy.

Results:

Of 457 participants, 11.2% reported being interested in taking chemoprevention, 40.9% reported no interest, and 47.9% reported being unsure about their interest in chemoprevention. Overall, interest in chemoprevention was not associated with individual Gail model breast cancer risk. In adjusted analysis, lack of interest among high-risk women was associated with low breast cancer worry and low perceived risk. Conversely, interest in chemoprevention among low risk women was associated with greater breast cancer worry. Age-related factors hypothesized to affect chemoprevention interest, including subjective life expectancy, increased comorbidity, and number of daily medications did not attenuate chemoprevention interest.

Conclusion:

Breast cancer worry and perceived breast cancer risk contribute to the lack of correlation between interest in breast cancer chemoprevention and objective breast cancer risk. Perceived life expectancy, increased comorbidity, and medication burden do not attenuate chemoprevention interest among older women.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA 295:2727–2741PubMedCrossRef Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA 295:2727–2741PubMedCrossRef
2.
Zurück zum Zitat Vogel V (2005) Chemoprevention in breast cancer. Clin Adv Hematol Oncol 3:531–533PubMed Vogel V (2005) Chemoprevention in breast cancer. Clin Adv Hematol Oncol 3:531–533PubMed
3.
Zurück zum Zitat Kinsinger LS, Harris R, Woolf SH et al (2002) Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:59–69PubMed Kinsinger LS, Harris R, Woolf SH et al (2002) Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:59–69PubMed
4.
Zurück zum Zitat Chlebowski RT, Collyar DE, Somerfield MR et al (1999) American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clinl Oncol 17:1939–1955 Chlebowski RT, Collyar DE, Somerfield MR et al (1999) American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clinl Oncol 17:1939–1955
5.
Zurück zum Zitat Levine M, Moutquin JM, Walton R et al (2001) Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative’s Steering Committee on clinical practice guidelines for the care and treatment of breast cancer. CMAJ 164:1681–1690PubMed Levine M, Moutquin JM, Walton R et al (2001) Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative’s Steering Committee on clinical practice guidelines for the care and treatment of breast cancer. CMAJ 164:1681–1690PubMed
6.
Zurück zum Zitat Lewis CL, Kistler CE, Amick HR et al (2006) Older adults’ attitudes about continuing cancer screening later in life: a pilot study interviewing residents of two continuing care communities. BMC Geriatr 6:10PubMedCrossRef Lewis CL, Kistler CE, Amick HR et al (2006) Older adults’ attitudes about continuing cancer screening later in life: a pilot study interviewing residents of two continuing care communities. BMC Geriatr 6:10PubMedCrossRef
7.
Zurück zum Zitat Kistler CE, Lewis CL, Amick HR et al (2006) Older adults’ beliefs about physician-estimated life expectancy: a cross-sectional survey. BMC Fam Prac 7:9CrossRef Kistler CE, Lewis CL, Amick HR et al (2006) Older adults’ beliefs about physician-estimated life expectancy: a cross-sectional survey. BMC Fam Prac 7:9CrossRef
8.
Zurück zum Zitat Bynum JPW, Braunstein JB, Sharkey P et al (2005). The influence of health status, age, and race on screening mammography in elderly women. Arch Intern Med 165:2083–2088PubMedCrossRef Bynum JPW, Braunstein JB, Sharkey P et al (2005). The influence of health status, age, and race on screening mammography in elderly women. Arch Intern Med 165:2083–2088PubMedCrossRef
9.
Zurück zum Zitat Mah Z, Bryant H (1992) Age as a factor in breast cancer knowledge, attitudes and screening behaviour. CMAJ 146:2167–2174PubMed Mah Z, Bryant H (1992) Age as a factor in breast cancer knowledge, attitudes and screening behaviour. CMAJ 146:2167–2174PubMed
10.
Zurück zum Zitat Black WC, Nease RF Jr., Tosteson AN (1995) Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87:720–731PubMedCrossRef Black WC, Nease RF Jr., Tosteson AN (1995) Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87:720–731PubMedCrossRef
11.
Zurück zum Zitat Smith BL, Gadd MA, Lawler C et al (1996) Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer. Surgery 120:297–303PubMedCrossRef Smith BL, Gadd MA, Lawler C et al (1996) Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer. Surgery 120:297–303PubMedCrossRef
12.
Zurück zum Zitat Bastian L, Lipkus I, Kuchibhatia M et al (2001) Women’s interest in chemoprevention for breast cancer. Arch Intern Med 161:1639–1644PubMedCrossRef Bastian L, Lipkus I, Kuchibhatia M et al (2001) Women’s interest in chemoprevention for breast cancer. Arch Intern Med 161:1639–1644PubMedCrossRef
13.
Zurück zum Zitat Gail MH, Costantino JP, Bryant J, et al (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedCrossRef Gail MH, Costantino JP, Bryant J, et al (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedCrossRef
14.
Zurück zum Zitat Doshi JA, Brandt N, Stuart B (2004) The impact of drug coverage on COX-2 inhibitor use in medicare. Health Aff Jan–Jun; Suppl Web Exclusives:W4-94-105 Doshi JA, Brandt N, Stuart B (2004) The impact of drug coverage on COX-2 inhibitor use in medicare. Health Aff Jan–Jun; Suppl Web Exclusives:W4-94-105
15.
Zurück zum Zitat Remington P, Smith M, Williamson D et al (1998) Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981–87. Public Health Rep 103:366–375 Remington P, Smith M, Williamson D et al (1998) Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981–87. Public Health Rep 103:366–375
16.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef
17.
Zurück zum Zitat Lerman C, Trock B, Rimer BK et al (1991) Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 114:657–661PubMed Lerman C, Trock B, Rimer BK et al (1991) Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 114:657–661PubMed
18.
Zurück zum Zitat Lerman C, Trock B, Rimer BK et al (1991) Psychological side effects of breast cancer screening. Health Psychol 10:259–267PubMedCrossRef Lerman C, Trock B, Rimer BK et al (1991) Psychological side effects of breast cancer screening. Health Psychol 10:259–267PubMedCrossRef
19.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef
20.
Zurück zum Zitat Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101PubMed Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101PubMed
21.
Zurück zum Zitat Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93–97PubMed Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93–97PubMed
22.
Zurück zum Zitat Kiefe C, Funkhouse E, Fouad M et al (1998) Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med 13:357–365PubMedCrossRef Kiefe C, Funkhouse E, Fouad M et al (1998) Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med 13:357–365PubMedCrossRef
23.
Zurück zum Zitat Diefenbach M, Miller S, Daly M (1999) Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychol 18:532–536PubMedCrossRef Diefenbach M, Miller S, Daly M (1999) Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychol 18:532–536PubMedCrossRef
24.
Zurück zum Zitat McCaul K, Branstetter A, Schroeder D et al (1996) What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. Health Psychol 15:423–429PubMedCrossRef McCaul K, Branstetter A, Schroeder D et al (1996) What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. Health Psychol 15:423–429PubMedCrossRef
25.
Zurück zum Zitat Bondy ML, Newman LA (2003) Breast cancer risk assessment models: applicability to African-American women. Cancer 97(1 Suppl):230–235PubMedCrossRef Bondy ML, Newman LA (2003) Breast cancer risk assessment models: applicability to African-American women. Cancer 97(1 Suppl):230–235PubMedCrossRef
26.
Zurück zum Zitat Greenlee RT, Hill-Harmon MB, Murray T (2001) Cancer Statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRef Greenlee RT, Hill-Harmon MB, Murray T (2001) Cancer Statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRef
27.
Zurück zum Zitat Yancik R, Wesley M, Ries L et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885–892PubMedCrossRef Yancik R, Wesley M, Ries L et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885–892PubMedCrossRef
28.
Zurück zum Zitat Stefanick ML (2006) Risk-benefit profiles of raloxifene for women. N Engl J Med 355:190–192PubMedCrossRef Stefanick ML (2006) Risk-benefit profiles of raloxifene for women. N Engl J Med 355:190–192PubMedCrossRef
29.
Zurück zum Zitat Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137PubMedCrossRef Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137PubMedCrossRef
30.
Zurück zum Zitat Gradishar WJ, Cella D (2006) Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA 295:2784–2786PubMedCrossRef Gradishar WJ, Cella D (2006) Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA 295:2784–2786PubMedCrossRef
31.
Zurück zum Zitat Mulley AG, Sepucha K. (2002) Making good decisions about breast cancer chemoprevention. Ann Intern Med 137:52–54PubMed Mulley AG, Sepucha K. (2002) Making good decisions about breast cancer chemoprevention. Ann Intern Med 137:52–54PubMed
Metadaten
Titel
Interest in breast cancer chemoprevention among older women
verfasst von
Jennifer Tjia
Ellyn Micco
Katrina Armstrong
Publikationsdatum
01.04.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9614-8

Weitere Artikel der Ausgabe 3/2008

Breast Cancer Research and Treatment 3/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.